An experimental drug combining nabilone and gabapentin reduced the severity and bothersomeness of cannabis withdrawal symptoms in a small randomized, placebo-controlled trial involving adults with
An Australian company has filed for approval of a THC-free CBD tablet it calls a world first for chronic pain. Its chief executive told 7News the trial didn’t outperform placebo.
Seven years ago, Ed Rosenthal’s PSA numbers spiked and a biopsy confirmed prostate cancer. He declined the interventions his doctor laid out, remained under active
Many patients find their doctors go quiet when medical cannabis comes up. Dr. Joseph Rosado explains why, from gaps in medical training to legal caution and lingering stigma, what the evidence actually supports, and the five questions that can turn a doctor’s silence into an informed conversation about benefits, risks and interactions.
Repeated CBG treatment prevented a long-term recognition memory deficit in male rats given MK-801, a compound used to model the cognitive impairments seen in schizophrenia. CBG did not restore the BDNF protein levels MK-801 had lowered, but it raised TrkB messenger RNA in the medial prefrontal cortex, pointing to a mechanism the researchers had not expected.
New Zealand has authorized two psychiatrists to prescribe pharmaceutical-grade MDMA to selected adults with PTSD, creating a tightly controlled treatment pathway while the drug remains officially unapproved.
A four-person Johns Hopkins pilot study found that 25 mg of oral THC could produce altered-state profiles that qualitatively resembled those seen with 25 mg of psilocybin, particularly when consumed in a setting modeled on psychedelic research. The sample is far too small to establish cannabis as a psychedelic, but the findings add to earlier research suggesting that dose, context, and individual response can push THC experiences into unexpectedly psychedelic-like territory.
Intense, slow and double puff. Researchers took a flowmeter to smoke sessions in five states, kept 51 usable readings and found the gentle pull moves more smoke than the hard one. All three profiles came in bigger than the cigarette settings cannabis smoke research has relied on for decades.
Someone bought fifteen cannabis products off Denver shelves and sent them to a lab. Two came back legal. On average the labels claimed 34.2% more THC than the products held. A Spanish engineer who has spent sixteen years scanning flower explains why the incentive to inflate runs through every link in the chain, why California calculates that fixing it costs four times what consumers would gain, and what would actually break the loop.
Doubling an inhaled dose of THC from 5 mg to 10 mg moves the self-reported high from 34 to 39 on a 100-point scale. The market spent 30 years chasing the number anyway. Four researchers on what a percentage does and doesn’t tell you, and what replaces it.
MoreBetter tracked 4,516 people across 36 hemp THC beverages for three weeks each. On days participants drank one, their modeled probability of also drinking alcohol fell from 22.9% to 10.9%, significant for 23 of the 36 products and moving the same direction in every case. Fifty days after the study ended, 63% of those surveyed said they were still drinking less. None of the 36 products would clear the federal cap arriving in November.
Every CBD-for-athletes pitch has sold recovery. A report on 47,522 patients who train and use medical cannabis points somewhere else entirely.
An experimental drug combining nabilone and gabapentin reduced the severity and bothersomeness of cannabis withdrawal symptoms in a small randomized, placebo-controlled trial involving adults with moderate-to-severe cannabis use disorder. The results offer an early signal of potential benefit, but with only 14 participants, a short study period and financial ties to the drug’s developer, much larger trials will be needed
An Australian company has filed for approval of a THC-free CBD tablet it calls a world first for chronic pain. Its chief executive told 7News the trial didn’t outperform placebo.
Seven years ago, Ed Rosenthal’s PSA numbers spiked and a biopsy confirmed prostate cancer. He declined the interventions his doctor laid out, remained under active surveillance and took CBD. A month ago, six biopsy cores, including samples from areas where cancer had previously been found, showed no cancer. When Colorado voters legalized cannabis in 2014, I was attending a big
Many patients find their doctors go quiet when medical cannabis comes up. Dr. Joseph Rosado explains why, from gaps in medical training to legal caution and lingering stigma, what the evidence actually supports, and the five questions that can turn a doctor’s silence into an informed conversation about benefits, risks and interactions.
Repeated CBG treatment prevented a long-term recognition memory deficit in male rats given MK-801, a compound used to model the cognitive impairments seen in schizophrenia. CBG did not restore the BDNF protein levels MK-801 had lowered, but it raised TrkB messenger RNA in the medial prefrontal cortex, pointing to a mechanism the researchers had not expected.
New Zealand has authorized two psychiatrists to prescribe pharmaceutical-grade MDMA to selected adults with PTSD, creating a tightly controlled treatment pathway while the drug remains officially unapproved.
A four-person Johns Hopkins pilot study found that 25 mg of oral THC could produce altered-state profiles that qualitatively resembled those seen with 25 mg of psilocybin, particularly when consumed in a setting modeled on psychedelic research. The sample is far too small to establish cannabis as a psychedelic, but the findings add to earlier research suggesting that dose, context, and individual response can push THC experiences into unexpectedly psychedelic-like territory.
Intense, slow and double puff. Researchers took a flowmeter to smoke sessions in five states, kept 51 usable readings and found the gentle pull moves more smoke than the hard one. All three profiles came in bigger than the cigarette settings cannabis smoke research has relied on for decades.
Someone bought fifteen cannabis products off Denver shelves and sent them to a lab. Two came back legal. On average the labels claimed 34.2% more THC than the products held. A Spanish engineer who has spent sixteen years scanning flower explains why the incentive to inflate runs through every link in the chain, why California calculates that fixing it costs four times what consumers would gain, and what would actually break the loop.
Doubling an inhaled dose of THC from 5 mg to 10 mg moves the self-reported high from 34 to 39 on a 100-point scale. The market spent 30 years chasing the number anyway. Four researchers on what a percentage does and doesn’t tell you, and what replaces it.
MoreBetter tracked 4,516 people across 36 hemp THC beverages for three weeks each. On days participants drank one, their modeled probability of also drinking alcohol fell from 22.9% to 10.9%, significant for 23 of the 36 products and moving the same direction in every case. Fifty days after the study ended, 63% of those surveyed said they were still drinking less. None of the 36 products would clear the federal cap arriving in November.
Every CBD-for-athletes pitch has sold recovery. A report on 47,522 patients who train and use medical cannabis points somewhere else entirely.
Get notified of our the latest cannabis news, exclusive brand deals, events updates and more!